A New Perspective on the Evaluation of Comorbidity Indices on Survival in Non-Small Cell Lung Cancer

Year 2023, , 764 - 768, 29.12.2023

Alev Bakır Kayı , Benan Müsellim

https://doi.org/10.33808/clinexphealthsci.1345763

Abstract

Objective: Mortality studies are interpreted by considering comorbid diseases related to the main disease. Existence, number, and type of comorbid diseases can have an important effect on prognosis. There are various comorbidity indices to include the effects of comorbid diseases in the model. With a new perspective, we aimed to emphasize the importance of evaluating the combination of comorbid diseases in cancer survival.
Methods: Retrospective cohort, data were collected from cases with Non-Small Cell Lung Cancer treated in Department of Chest Diseases. Initially, the effects of their comorbid diseases on the duration of survival were calculated with univariate analysis, then examined according to number of comorbidities, lastly their specific combinations' Hazar Ratio were calculated with Cox multivariate analysis. The most used comorbid indices in the literature were also included.
Results: Out of 247 non-small cell lung cancer (NSCLC) cases analysis, 220 (89%) were men. Median duration of follow-up was 277 days, at the end of the follow-up 197 cases had died. HR of two comorbid diseases in cases was 1.80, but 59.52 for the combination of “diabetes and interstitial lung disease” and 3.76 for “diabetes and previously cancer”. Existing comorbid indices had no significant effect on survival time (p:0.684; 0.101; 0.273; 0.567, respectively).
Conclusion: We have offered a new perspective which takes into comorbid diseases related to main disease and specially their combinations when the risk is estimated in survival research. Accurate assessments of the list of comorbid diseases related to main disease hold significant importance in advancing this field.

Keywords

Comorbidity index, comorbid disease, survival analysis, non-small cell lung cancer

Supporting Institution

-

Project Number

-

Thanks

Thanks to Mustafa Şükrü ŞENOCAK for his valuable ideas and contributions.

References

• Birim, Özcan, A. Pieter Kappetein, and Ad JJC Bogers. Charlson comorbidity index as a predictor of long-term outcome after surgery for nonsmall cell lung cancer. Int Congr Ser. 2005;28(5): 759-762. DOI:10.1016/j.ejcts.2005.06.046
• Groll D.L., To T., Bombardier C., Wright J.G. The development of a comorbidity index with physical function as the outcome. J Clin Epidemiol. 2005;58(6):595-602. DOI:10.1016/j.jclinepi.2004.10.018.
• Hall S.F. A user's guide to selection a comorbidity index for clinical research. J Clin Epidemiol. 2006;59(8):849-855. DOI:10.1016/j.jclinepi.2005.11.013
• Feinstein, Alvan R. The pre-therapeutic classification of co-morbidity in chronic disease. Journal of Chronic Diseases 1970;23(7):455-468. DOI:10.1016/0021-9681(70)90054-8
• Tomoki Yamano, Shinichi Yamauchi, Kei Kimura, Akihito Babaya, Michiko Hamanaka, Masayoshi K. Influence of age and comorbidity on prognosis and application of adjuvant chemotherapy in elderly Japanese patients with colorectal cancer: A retrospective multicentre study. European Journal of Cancer 2017;81:90-101. DOI:10.1016/j.ejca.2017.05.024
• Diana Sarfati. Review of methods used to measure comorbidity in cancer populations: no gold standard exists. Journal of Clinical Epidemiology 2012;65(9):924-933. DOI:10.1016/j.jclinepi.2012.02.017
• De Groot, V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity: A critical review of available methods. J Clin Epidemiol. 2003;56(3):221-229. DOI:10.1016/S0895-4356(02)00585-1
• Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer. 2000;36(4):453-471. DOI:10.1016/S0959-8049(99)00319-6
• Licia D, Andrea A, Monica C, Fabiola G, Umberto S, Gian PC. Validity of the modified charlson comorbidity index as predictor of short-term outcome in older stroke patients. Journal of Stroke and Cerebrovascular Diseases 2015;24(2):330-336. DOI:10.1016/j.jstrokecerebrovasdis.2014.08.034
• Anne E, Claudias T, Roberth A, Rosanna MC. Comorbidity measures for use with administrative data. Medical Care 1998;36(1):8-27.
• Mette CN, Cecilie DS, Sofie LA, Bent O, Jarle C, Claus H. A new clinically applicable age-specific comorbidity index for preoperative risk assessment of ovarian cancer patients. Gynecologic Oncology 2016;141(3):471–478. DOI:10.1016/j.ygyno.2016.03.034
• Şenocak M.Ş. Biyoistatistik ve Araştırma Yöntembilimi. İstanbul Tıp Kitabevi; 2014. (Turkish)
• Şenocak M.Ş. Özel Biyoistatistik: Epidemiyolojide Sayısal Çözümleme. Çağlayan Kitabevi; 1992. (Turkish)
• Kachigan SK. Multivariate Statistical Analysis: A conceptual introduction. Radius Press; 1991.
• Kachigan SK. Statistical Analysis: An interdisciplinary introduction to univariate & multivariate methods. Radius Press; 1986.
• Miller R. G. Survival Analysis. New York: John Wiley and Sons Inc.; 1998.
• Hyun-Ju S, Seok-Jun Y, Sang-Il L, Kun SL, Young HY, Eun-Jung K. A comparison of the Charlson comorbidity index derived from medical records and claims data from patients undergoing lung cancer surgery in Korea: A population-based investigation. BMC Health Services Research 2010;10(1):1-8.
• Larry B. Goldstein, Gregory P. Samsa, David B. Matchar and Ronnie D. Horner. Charlson Index comorbidity adjustment for ischemic stroke outcome studies. Stroke 2004;35(8):1941-1945. DOI:10.1161/01.STR.0000135225.80898.1c
• De Rijke JM, Schouten LJ, Ten Velde GPM, Wanders SL, Bollen ECM, Lalisang RI. Influence of age, comorbidity and performance status on the choice of treatment for patients with non-small cell lung cancer; results of a population-based study. Lung Cancer 2004;46(2):233-245.
• Lembicz M, Gabryel P, Brajer-Luftmann B, Dyszkiewicz W, Batura-Gabryel H. Comorbidities with non-small cell lung cancer: Is there an interdisciplinary consensus needed to qualify patients for surgical treatment? Annals of Thoracic Medicine 2018;13(2):101-107.
• Birim Ö, Maat APWM, Kappetein AP, Van Meerbeeck JP, Damhuis RAM, Bogers AJJC. Validation of the Charlson comorbidity index in patients with operated primary non-small cell lung cancer. European Journal of Cardio-Thoracic Surgery 2003;23(1):30-34.
• Nicolucci A, Cubasso D, Labbrozzi D, Mari E, Impicciatore P, Procaccini DA. Effect of coexistent diseases on survival of patients undergoing dialysis. ASAIO J. 1992;38(3):M291-295.
• Mohamed L. Sorror, Michael B. Maris, Rainer Storb, Frederic Baron, Brenda M. Sandmaier, David G. Maloney. Hematopoietic cell transplantation (HCT)–specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106(8):2912-2919. 10.1097/00002480-199207000-00040
• C. Hudon, M. Fortin, A. Vanasse. Cumulative Illness Rating Scale was a reliable and valid index in a family practice context. Journal of Clinical Epidemiology 2005;58(6):603–608. DOI:10.1016/j.jclinepi.2004.10.017